The founder of the nonprofit Little Legs Big Heart talks about her approach to promoting community and inclusion among those impacted by skeletal dysplasia. The renowned dealmaker and our Chief Business Officer discusses the qualities that attracted him to BioMarin — and why those same attributes also make the company an enticing business partner.
We relentlessly pursue bold science to translate genetic discoveries into new medicines that advance the future of human health. We listen to and learn from patient communities to collaborate on solutions with the potential to help improve care.
Our talented and dedicated people represent the best the biotech industry has to offer and have helped shape a culture focused on working together to deliver for the patients we serve.
Learn More. Our approved medicines treat achondroplasia, severe hemophilia A and several rare inherited and lysosomal storage diseases. Today at the J. Morgan Healthcare Conference, our President and CEO Alexander Hardy and members of the BioMarin Leadership Team highlighted our continued progress against our strategy and how we are poised to deliver innovation for patients and families for decades to come. View Post. As we wrap up this year and look ahead to , we are more driven than ever to deliver on our purpose: to be the biotech leader that translates the promise of genetic discovery into medicines that make a profound impact on the life of each patient.
The BioMarin 8 — our core Operating Principles — provide the framework for how we work together every day to fulfill that purpose. Thank you to all our employees for your hard work and dedication throughout — we look forward to what we will accomplish together in the new year. Explore Opportunities. Links to sites outside of this website are provided as a resource to the viewer.
